FEATURED SESSIONS:

**MEDIMMUNE** Grasps the Commercial Transfer Needs of Advanced Biologics
Brandon Christensen
Manager, Biopharmaceutical Tech Transfer and Manufacturing Support

**GENZYME** Uses Creative Models for Risk-Based Equipment Design
Zheng Huang
Senior Manager, Global Manufacturing Science and Technology

**MERCK** Emphasizes Transparency in Project Manager Skill Sets
John Bowers
Senior Principal Scientist, Biopharmaceutical Engineering

**PFIZER** Adjusts Technology Transfer Pipelines for Antibody-Drug Conjugates
Vincent Turula
Director, Biotherapeutics Outsourcing Management

**BIOGEN IDEC** Balances the Risks of Accelerated Tech Transfer
Tracy Ahrens
Tech Transfer Leader

The ONLY event to focus specifically on the skill sets needed for managing, documenting and benchmarking quality control during every step of internal and outsourced tech transfer and scale-up.

**ALL-NEW CASE STUDIES ILLUSTRATE HOW TO:**

- Identify the Unique Challenges of Transferring Processes for Biosimilars
- Adapt Your Biologics Transfer Tool Kit to New Molecular Types
- Accelerate Your Upscaling Methods for Well-Characterized Biologics
- Design Hybrid Facilities that Streamline Technology Transfers
- Cultivate Transparency and Cross-Discipline Expertise in Tech Transfer Project Managers

“Excellent, comprehensive presentations and case studies.”
— Director, CMC Team Lead, ALLERGAN

“Strong content on technical requirements and challenges for method transfer, from obvious subject matter experts.”
— Associate Director, External Manufacturing, SHIRE

For More Information Call 866–207–6528 or Visit www.exlevents.com/techtransfer
Dear Colleague,

All biotech manufacturing, processing, engineering and outsourcing professionals are responsible for maintaining biologic quality and avoiding contamination. This constant requirement spells the difference between success and failure, and it grows ever harder when you must duplicate and transfer your processes to new facilities — whether internal or external — and when upscaling to commercial biologic production. Missed deadlines in either of these processes can lead to unintended consequences and heavy costs for your company.

In addition to the longstanding challenges of biologics process transfer, the industry now faces more advanced obstacles in technical development and outsourcing. Most biotherapeutics are monoclonal antibodies, but increasingly more represent advanced types of molecules such as antibody-drug conjugates, which need greater care in their handling and transfer. At the same time, economic and capacity pressures have led to greater industry expansion into developing countries, where systemic maturity differences may put quality control and transparent documentation at risk.

ExL Events’ 2nd Technology Transfer for Biologics conference is the only event to focus specifically on developing the ideal skill sets, training, documentation and process practices to ensure biologics quality during and after method transfer. This year’s program features all-new case studies built around our audience’s most urgent questions, sharing best practices on how to:

- Establish transparent and reliable communication and documentation systems among tech transfer project managers and teams
- Proactively protect biologic quality when changing raw material sourcing and manufacturing partners
- Set the best balance for permanent, single-use and hybrid facilities when upscaling biologic production
- Adapt your biologic pipeline to accommodate novel molecules such as antibody-drug conjugates
- Bridge cultural and experience gaps when transferring bioprocesses to developing countries

Don’t miss this opportunity to network with biomanufacturing leaders at this unique event dedicated to a skill set that is often overlooked yet crucial for your pipeline success!

We look forward to welcoming you to Boston this fall.

Sincerely,

Matt Greenbaum
Production Team Leader
ExL Events
mgreenbaum@exlevents.com

"Great examples of strategies to employ during technology transfer and methods to avoid wasted time and money.”

— Associate Manufacturing Engineer, MERRIMACK PHARMA

For More Information Call 866–207–6528 or Visit www.exlevents.com/techtransfer
NEW MOLECULES AND NEW ENVIRONMENTS FOR TECH TRANSFER

9:00 LEVERAGE ANALYTICAL TECHNOLOGY PLATFORMS TO ACCELERATE PRODUCT AND PROCESS DEVELOPMENT AND TO MITIGATE RISKS ASSOCIATED WITH TECHNICAL TRANSFER

Traditionally, the upscaling of biologics production involved stepwise increases in bioreactor size, checking at each level to observe product quality. But there may be circumstances where some of these intermediate steps can be omitted, especially if you are working with a particularly well-characterized monoclonal antibody. When can you accelerate upscaling by omitting intermediate steps, and what are the skill sets necessary to make sure quality doesn’t decline?

- Map the different pathways for a 50-fold increase in bioreactor size
- Determine when bioreactor size multiplication will be acceptable
- Perform risk analysis to clarify how your scaling exercise will unfold

Hemant Kumar, Senior Director, Quality, GENZYME

9:40 MODIFY PIPELINES TO ADJUST TO NEW MOLECULES

In the recent past, most of the biotech pipeline consisted of monoclonal antibodies. While these molecules are still significant, more companies have begun diversifying into new molecule candidates, such as antibody-drug conjugates, fusion proteins and bacterial cell cultures. What new methodologies are necessary to update your technology transfer skills for working with these molecules?

- Develop site and relocating methods for molecules with unique transportation needs
- Adapt sending and receiving analytical methods for ADC challenges
- Grasp the clinical and commercial transfer needs for advanced biologics

Vincent Turula, Director, Biotherapeutics Outsourcing Management, PFIZER

10:20 CASE STUDY: THE UPSTREAM PERSPECTIVE FOR TECHNOLOGY TRANSFER OF NOVEL MOLECULES

Manufacture of novel molecules is increasingly taking place in facilities traditionally oriented around monoclonal antibody cell cultures. This changeover brings with it new demands that require process design and equipment adaptation.

- Modify plant capabilities to accommodate the constraints associated with new molecules
- Evaluate the limits of traditional process boundaries
- Support adoption of new process alternatives

Mark Meyers, Manager, Bioprocess Engineering, MEDIMMUNE

11:00 NETWORKING BREAK

11:30 CASE STUDY: SPECIAL CONSIDERATIONS FOR DOWNSTREAM NOVEL MOLECULE TECH TRANSFER

As biologic pipelines diversify away from monoclonal antibodies, the rising emphasis on novel molecules is driving new methods of assessment and changes to tech transfer procedures.

- Assess fit-to-plant in light of increased process variability
- Understand and expand equipment capability
- Demonstrate feasibility of downstream transfer approaches

Brandon Christensen, Manager, Biopharmaceutical Tech Transfer and Manufacturing Support, MEDIMMUNE

12:10 PLAN FOR TECHNOLOGY TRANSFER AND SCALE-UP OF A BIOSIMILAR CELL CULTURE MANUFACTURING PROCESS

Bench scale bioreactors are used during development of a biosimilar to adjust product quality attributes of the protein of interest to be “highly similar” to those of the branded product. Once these attributes have been established at the benchtop scale, the scale-up (either internal or external) requires that quality remain consistent with the branded product across all scales. In contrast to a new drug development program, a biosimilar is scaled with the intent that material will be manufactured using the final manufacturing process and ready for market. Though traditional parameters such as P/V, mixing time and set points are used for scale-up, a biosimilar process requires that these parameters and operating conditions be maintained in a narrow operating range usually tighter than is required for a new drug process.

- Manipulate biosimilar product quality with process levers to maintain similarity with the branded product
- Identify the unique challenges of transferring a biosimilar process to a CMO
- Solve the added complexities of working within a three-way partnership

Brett Belongia, Associate Director, Biologics Development, MOMENTA

12:50 CLARIFY TECHNIQUES TO ACCOMMODATE HIGHER DENSITIES AND TITERS FOR UPSTREAM-TO-DOWNSTREAM TRANSFERS AND UPSCALING

Throughout the biotech industry, cell densities and protein titers are getting steadily higher, which places more pressure on process robustness downstream and adds to the risk of product impurities. This increased downstream burden, combined with scale-up considerations, can cause extra process stresses. Development scientists must be adept at all the technological tools for maintaining quality control.

- Utilize alternate clarification techniques to reduce product impurities and enhance separations
- Proceed with purification techniques typical to traditional processes
- Learn from case studies on both bacterial fermentation and mammalian cell cultures

Kathryn Golden, Senior Scientist, Manufacturing and Process Sciences, ELEVEN BIOTHERAPEUTICS

1:30 LUNCHEON

PARTNERSHIPS, PROJECT MANAGEMENT AND PREPARATION FOR TECH TRANSFER

2:30 BUILD MODELING TOOL KITS TO FACILITATE PROCESS ADAPTATION AND TECHNOLOGY TRANSFER

How can refinements to your modeling techniques lead to more streamlined technology transfer? A good operational model can pre-empt potential bottlenecks in your GMP campaigns, and can also clarify how the equipment in your facility can best be leveraged to support operations. CFD and first principles modeling approaches were tightly integrated in overall Quality by Design approaches. Off-the-shelf software, home-growth model and innovative experimental techniques are combined to generate pragmatic yet creative solutions to successful process adaptation.

- Leverage CFD, operational and first principles models for science and risk-based equipment, process, and facility design
- Look deeper into various technology transfer phases to avoid discovering problems too late
- Use model and small-scale data to define the operation space for at-scale equipment, and get right-first-time results during engineering campaigns

Zheng Huang, Senior Manager, Global Manufacturing Science and Technology, GENZYME

3:10 EMPHASIZE COMMUNICATION AND TRANSPARENCY IN PROJECT MANAGER SKILL SETS

Cross-team colleagues may be reluctant to critique each other or admit to gaps in their own knowledge. The best managers establish a non-punitive atmosphere in which members can comfortably disclose concerns.

- Explore the feasibility and pros and cons of full-time devoted technology transfer project managers
- Invite crucial feedback from upstream, downstream, analytical and formulation team representatives
- Benefit from merging cross-disciplinary expertise on manufacturing and regulatory expectations

John Bowers, Senior Principal Scientist, Biopharmaceutical Engineering, MERCK

For More Information Call 866–207–6528 or Visit www.exlevents.com/techtransfer
PANEL DISCUSSION: PROCESS FIT TO PLANT IMPACT ON PROCESS DEVELOPMENT LIFE CYCLE MANAGEMENT, EQUIPMENT STANDARIZED AND CMC SUCCESS
Successful implementation of a process at scale is a CMC program success indicator. Process Fit to Plant (PFP) exercises can define process development targets and maximize the likelihood of technology transfer success. For an organization with a network of facilities across different scales, the usefulness of PFP depends on the level of equipment standardization.

- Examine how equipment standardization can be achieved
- Grasp relevance of standardization to operations and CMC success
- Ensure proficiency with PFP techniques

Amos Tsai, Principal Scientist, JOHNSON & JOHNSON

11:00 ENSURE EARLY QA INVOLVEMENT AND THE USE OF QUALITY IMPROVEMENT TOOLS TO INCREASE THE LIKELIHOOD OF TECH TRANSFER SUCCESS
Your QA team should get involved with technology transfer proposal reviews from the very earliest stages. PDA Technical Report 65 described best practices for future technology transfers, and you can build a bespoke process around your needs using these practices as a road map for both internal and outsourced transfers.

- Use Six Sigma quality improvement tools to identify key processes and requirements specific to your project
- Create processes more likely to succeed
- Identify and learn from past instances where QA teams were invited too late — at the interim or even the final review

Amnon Eylath, Senior Director, Quality Assurance, GENZYME

5:40 END OF DAY ONE

TUESDAY, OCTOBER 6, 2015 // DAY TWO

8:00 REGISTRATION AND CONTINENTAL BREAKFAST

6:30 CMC TEAM BREAKOUTS

8:45 CHAIRPERSON’S RECAP OF DAY ONE
Brandon Christensen, Manager, Biopharmaceutical Tech Transfer and Manufacturing Support, MEDIIMMUNE

9:00 BALANCE THE RISKS, SPECIALIZATIONS AND STANDARIZED TO EXECUTE AN 8-WEEK TECH TRANSFER
Billon-dollar site depreciation is expensive. Speed induces risk. So how do you maximize facility utilization and balance limited resources to support a high velocity for tech transfers? Learn how Biogen successfully executes on a multi-product production schedule ranging from first-in-human, clinical, commercial and CMO programs.

- Understand phase-appropriate definitions of success for clinical versus commercial production
- Manage CMO relationships and platform process development
- Transfer process-operating parameters with known process knowledge gaps with speed, accuracy and flexibility

Tracy Ahrens, Tech Transfer Leader, BIOGEN IDEC

9:45 BUILD A DECISION TREE THAT OPTIMIZES FLEXIBILITY AND SPEED IN TECHNOLOGY TRANSFER
Many biologics companies chase similar therapeutic targets and markets, so being the first to market is critical. One of the most basic and unchanging needs for biologics manufacturers is to decrease production time without compromising quality.

- Structure your facility choices to allow for the best potential manufacturing pipeline
- Survey the competitive landscape in line with corporate priorities to determine which molecules to manufacture and whether to keep technology transfers internal or outsourced
- Fit your processes to your plant assessment to be sure that your facilities can handle the necessary transfers

Fauad Hasan, Director, CMC Teams, ALLERGAN

11:00 MANAGE YOUR TECHNOLOGY TRANSFERS WITH AN EMPHASIS ON SYSTEM ROBUSTNESS
When you transfer from one CMO to another, you may find yourself having to upscale processes at the same time. If you transfer at an early stage, you may have little data or non-robust systems and your vendor may not be able to meet your raw materials needs.

- Make process changes as needed based on gaps in facility capacity
- Transition to larger-scale vendors who can overcome raw material challenges
- Maintain flexibility with analytics, skill sets and the outcomes of processes

Stephen Gacheru, Project Lead, TPM Group, BRISTOL-MYERS SQUIBB

1:30 ADVANCE FROM LEGACY PRODUCT STANDARDS TO NEXT-GENERATION PROCESSES
The majority of all biologics in the industry’s pipeline today are monoclonal antibodies, which allows for the adoption of similar generic platforms. But legacy products, in development for 10 years or more, inherit older processes that are not as robust. While it is typical to expect that commercial-ready processes are the most mature and are capable of a generic approach, using older legacy processes requires constant management and triggers a debate on whether to launch a second generation.

- Weigh the pros and cons of updating legacy processes
- Quantify the requirements, in both time and money, for refiling processes in multiple global markets
- Determine when the savings in process problems and costs outweighs the regulatory challenges after an update

Gene Mehr, Senior Engineer II, BIOGEN IDEC

2:15 BUILD A SENSE OF INVESTMENT IN TEAM MEMBERS TO AVOID INFORMATION SLOWDOWNS
Successfully matching your lab scale production with clinical and commercial scales requires much more than filling out documents or monitoring technical parameters. To drive success you must establish a sense of ownership within process developers and manufacturers, so every stakeholder works together to establish a system that can run on scheduled meetings.

- Establish process walkthrough schedules and regular group record sign-offs
- Transition from a “box-checking” mentality to one that equips teams to understand and react to nuances
- Empower your teams to rapidly adjust to changes in a manner better than an educated guess

Venkat Koganti, Associate Director, Formulation and Process Development, CELSION CORPORATION

3:00 CONFERENCE CONCLUDES
Registration fees for attending ExL’s 2nd annual Technology Transfer for Biologics conference:

**EARLY BIRD PRICING** Register Before Friday, August 21, 2015 $1,895

**STANDARD PRICING** Register After Friday, August 21, 2015 $2,095

**ONSITE PRICING** $2,195

**Group Discount Programs**

Offers cannot be combined. Early Bird rates do not apply. To find out more on how you can take advantage of these group discounts, call 866–207–6528.

**Save 25% per person when registering four**
For every three simultaneous registrations from your company, you will receive a fourth complimentary registration to the program (must register four at one time).

**Save 15% per person when registering three**
Can only send three? You can still save 15% off of each registration.

**Terms & Conditions**

By registering for an ExL Events, Inc. (“ExL Pharma”) event, you agree to the following set of terms and conditions listed below:

**Registration Fee:** The fee includes the conference, all program materials, and designated continental breakfasts, lunches and refreshments.

**Payment:** Make checks payable to ExL Events, Inc. and write code C623 on your check. You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full prior to the commencement of the conference. Any discount applied cannot be combined with any other offer, and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options.

**Cancellation and Refund Policy:** If you need to cancel your registration for an upcoming ExL event, please note the following policies derived from the Start Date of the event:
• Four weeks or more: A full refund (minus a $295 processing fee) or a voucher to another ExL event valid for 12 months from the voucher issue date.
• Less than four weeks: A voucher to another ExL event valid for 12 months from the date of voucher issue.

If you cancel at any time after receiving the conference documentation, the voucher issued will be $395 less.

**Credit Vouchers:** Vouchers are valid toward one (1) ExL Event of equal or lesser value. If the full amount of said voucher is not used at time of registration, any remaining balance is no longer applicable now or in the future. Once a Credit Voucher has been applied toward a future event, changes cannot be made. In the event of cancellation on the attendees’ behalf, the Credit Voucher will no longer be valid.

**QUESTIONS? COMMENTS?**

Do you have any questions, comments on the program, or specific topics you would like addressed? Would you like to get involved as a speaker, moderator or discussion leader? Please email the Production Team Leader, Matt Greenbaum at mgreenbaum@exlevents.com.

**Substitution Charges:** There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference.

ExL Events reserves the right to cancel any conference it deems necessary and will not be responsible for airfare, hotel or any other costs incurred by registrants.

ExL Events’ liability is limited to the conference registration fee in the event of a cancellation and does not include changes in program date, content, speakers or venue.

*The opinions of ExL speakers do not necessarily reflect those of the companies they represent or ExL Events, Inc.

Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, significant effort to find a suitable replacement will be made.

The content in ExL slide presentations, including news, data, advertisements and other information, is provided by ExL Events, Inc.’s (“ExL’s”) designated speakers and is designed for informational purposes for its attendees. It is NOT INTENDED for purposes of copywriting or redistribution to other outlets without the express written permission of ExL’s designated speaking parties. Neither ExL nor its content providers and/or speakers and attendees shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. ExL EVENTS, INC. EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY THE CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE. Although ExL makes reasonable efforts to obtain reliable content from third parties, ExL does not guarantee the accuracy of or endorse the views or opinions given by any third party content provider. While ExL presentations may point to other Internet sites that may be of interest to you, ExL does not endorse or take responsibility for the content on such other sites.
5 Ways to Register

www.exlevents.com/techtransfer
registration@exlevents.com
866-207-6528

☐ Yes! Register me for the conference!

Name: __________________________ Title: __________________________
Company: __________________________
Dept.: __________________________
Address: __________________________
City: __________________________ State: __________________________ Zip: __________________________
Email: __________________________ Phone: __________________________ Fax: __________________________

Method of Payment: ☐ Check ☐ Credit Card
Make checks payable to ExL Events, Inc.

Card Type: ☐ MasterCard ☐ Visa ☐ Discover ☐ AMEX

Card Number: __________________________ Exp. Date: __________________________

Name on Card: __________________________ Signature: __________________________

Please contact me:
☐ I’m interested in marketing opportunities at this event
☐ I wish to receive email updates on ExL Pharma’s upcoming events

ExL Events, Inc.
494 8th Avenue, Fourth Floor
New York, NY 10001

CONFERENCE CODE: C623

2nd TECHNOLOGY TRANSFER FOR BIOLOGICS
Maintaining Quality, Speed and Flexibility in the Replication of Biologics Manufacturing as You Expand to New Molecules and Markets

October 5-6, 2015 | Hilton Boston Back Bay | Boston, MA

Brandon Christensen
Manager, Biopharmaceutical Tech Transfer and Manufacturing Support
MEDIMMUNE

Zheng Huang
Senior Manager, Global Manufacturing Science and Technology
GENZYME

John Bowers
Senior Principal Scientist, Biopharmaceutical Engineering
MÉRCK

Vincent Turula
Director, Biotherapeutics Outsourcing Management
PFIZER

Tracy Ahrens
Tech Transfer Leader
BIOGEN IDEC

For More Information Call 866–207–6528 or Visit www.exlevents.com/techtransfer